#VRXA
VERAXA Biotech (NASDAQ: VRXA) is advancing cancer drug development using human-relevant NAMs models, cutting animal use by 95% while demonstrating potent tumor-cell killing across 10 patient-derived lung cancer models. #Biotech #Oncology
November 4, 2026 at 9:17 PM
VERAXA Biotech (NASDAQ: VRXA) is adopting FDA-aligned New Approach Methodologies to advance its BiTAC cancer pipeline, cutting animal use dramatically while generating more human-relevant preclinical data. #Oncology #Biotech
November 3, 2026 at 7:13 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its BiTAC platform, designed to activate cancer-killing activity only when two molecules recognize targets on the same tumor cell. Preclinical results show improved safety and comparable efficacy to conventional therapies. #Oncology #Biotech
November 3, 2026 at 6:57 PM
VERAXA Biotech (VRXA) is adopting FDA-aligned New Approach Methodologies to advance its cancer pipeline with fewer animals and more human-relevant data. An ex vivo lung cancer study used ~10 mice vs. an estimated 200+ for comparable in vivo work. #Oncology #Biotech
November 3, 2026 at 6:11 PM
🚨 $VRXA
Gruninger Marc () bought 10,000 shares at an average price of $0.9983 per common share. (Date: 2026-10-28)
SEC Filing: VRXA
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 8:53 PM
Gruninger Marc, Director at $VRXA, raised their own stake by 1053% — bought 9,133 shares (~$9K) on the open market.
https://insiderbid.com/insider/0002128575
October 29, 2026 at 8:54 PM
Veraxa Biotech AG - Post de-SPAC ($VRXA) – Insider Purchase

• Insider: Marc Gruninger, Director
• Bought: 10,000 shares (about $10K)
• Price: about $1.00 a share · Oct 27-28
• Filed: Oct 29 · Form 4

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderBuying #Stocks
Marc Gruninger (Director) bought $10K of Veraxa Biotech AG - Post de-SPAC ($VRXA)
Form 4 filed Oct 29. Every line of the filing.
elixstocks.com
October 29, 2026 at 8:54 PM
$VRXA: director Christoph Samuel Ziegler reported purchasing $33k of shares on Oct 20. Activity Score 33/100.
https://yarako.com/insider-buying/VRXA

Data from SEC Form 4 filings. For information only. Not investment advice. Past insider purchases do not predict future returns.
$VRXA insider purchases on Yarako
Open-market insider purchases reported on SEC Form 4. Information only, not advice.
yarako.com
October 27, 2026 at 7:24 PM
#$VRXA Veraxa Biotech AG - Post de-SPAC
Director Christoph Samuel Ziegler bought $32,700 of shares on 20 Oct (SEC filing, 21 Oct).
Holding ×4.8

Every real insider buy, noise removed: chalni.com
#insiderbuying #stocks
Real insider buys, last 5 trading days · Chalni
Top managers and directors buying their own company's shares, from SEC Form 4 filings. Pay plans, funds, pre-planned trades and private deals removed.
chalni.com
October 22, 2026 at 11:52 AM
Ziegler Christoph Samuel, Director at $VRXA, raised their own stake by 378% — bought 30,000 shares (~$33K) on the open market.
https://insiderbid.com/insider/0002123272
October 21, 2026 at 8:18 PM
Veraxa Biotech AG - Post de-SPAC ($VRXA) – Insider Purchase

• Insider: Christoph Samuel Ziegler, Director
• Bought: 30,000 shares (about $33K)
• Price: about $1.09 a share · Oct 20

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderBuying #Stocks
Christoph Samuel Ziegler (Director) bought $33K of Veraxa Biotech AG - Post de-SPAC ($VRXA)
Form 4 filed Oct 21. Every line of the filing.
elixstocks.com
October 21, 2026 at 8:19 PM
WxW put up Pac vs Generico from 2007s 16 carat Gold tournament; not their first match, albeit WxW was where they first faced each other the previous year

m.youtube.com/watch?v=vrxA...
FULL MATCH: In Memory of PAC - El Generico vs. PAC - wXw 16 Carat Gold 2007
YouTube video by Westside Xtreme Wrestling (wXw)
m.youtube.com
October 15, 2026 at 10:03 PM
VERAXA Biotech (NASDAQ: VRXA) unveiled first in vivo data showing significant tumor regression from its BiTAC-ADC platform at the World ADC Congress — with no body weight loss and a promising safety profile. A potential step forward in targeted cancer therapy. #Oncology #Biotech
October 14, 2026 at 9:20 PM
VERAXA Biotech (NASDAQ: VRXA) unveiled first in vivo data showing tumor regression in breast cancer models using its BiTAC-ADC platform — with no body weight loss observed. Early results suggest strong efficacy and improved safety vs. conventional ADCs. #Oncology #Biotech
October 13, 2026 at 9:10 PM
VERAXA Biotech (NASDAQ: VRXA) used just 10 mice — vs. an estimated 200+ — to evaluate its cancer therapy pipeline using FDA-aligned New Approach Methodologies, cutting costs and timelines without compromising results. #Biotech #Innovation
October 10, 2026 at 6:51 PM
VERAXA Biotech (VRXA) is using FDA-aligned New Approach Methodologies to slash animal testing in cancer drug development — achieving comparable results with 10 mice instead of 200+. A potential game-changer for preclinical efficiency and ethics. #Biotech #CancerResearch
October 10, 2026 at 6:44 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
October 9, 2026 at 6:56 PM
VERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
October 9, 2026 at 6:56 PM
VERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech
October 9, 2026 at 6:43 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its Nasdaq debut. Parent company Xlife Sciences reports strong H1 progress across a portfolio backed by 416 patents. #Biotech #Oncology
October 9, 2026 at 6:01 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its 'AND-gated' BiTAC cancer platform following its NASDAQ debut in June 2026. Early preclinical data and key leadership hires signal the Swiss biotech is gaining momentum in oncology drug development. #Oncology #Biotech
October 9, 2026 at 6:25 PM
VERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its June 2026 Nasdaq debut. Parent Xlife Sciences reports H1 portfolio progress across diagnostics, AI, and pharma, backed by 416 patents. #Oncology #Biotech
October 9, 2026 at 5:54 PM
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 bispecific ADC into preclinical studies after completing discovery-phase collaboration with OmniAb. The 'AND-gate' design targets two tumor antigens simultaneously, aiming for greater cancer-cell selectivity. #Biotech #Oncology
October 9, 2026 at 4:26 PM
Small-cap stocks oversold with improving relative strength, Wed Oct 7th - #$XTIA #$DKI #$BIYA #$VRXA #$MNPR #$LX #$LWAY #$DRUG #$ASMB #$RC - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Wednesday October 7, 2026 – Crystal Equity Research
crystalequityresearch.com
October 7, 2026 at 10:05 PM